Frequency of relocalization at the B-CLL/L-fibroblast contact areas
. | 0 min, % . | . | 10 min, % . | . | 30 min, % . | . | 60 min, % . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecule . | L-CD31+ . | L-mock . | L-CD31+ . | L-mock . | L-CD31+ . | L-mock . | L-CD31+ . | L-mock . | ||||
| CD38 | 5.3 ± 3.2 | 7.4 ± 3.8 | 58.2 ± 9.1 | 8.3 ± 4.8 | 65.5 ± 11.4 | 12.7 ± 7.5 | 22.2 ± 9.7 | 9.1 ± 5.9 | ||||
| CD19 | 8.6 ± 4.1 | 5.9 ± 2.4 | 44.3 ± 8.7 | 9.5 ± 6.3 | 57.9 ± 8.9 | 7.5 ± 5.4 | 15.6 ± 8.4 | 5.7 ± 4.4 | ||||
| slgM | 6.5 ± 4.3 | 6.8 ± 2.7 | 37.9 ± 11.4 | 7.8 ± 1.4 | 44.6 ± 7.9 | 3.2 ± 2.8 | 18.8 ± 6.9 | 7.4 ± 3.9 | ||||
| HLA class I | 4.7 ± 2.8 | 7.1 ± 3.3 | 7.5 ± 5.9 | 8.4 ± 4.2 | 4.2 ± 3.5 | 8.4 ± 5.2 | 9.3 ± 3.5 | 6.6 ± 5.1 | ||||
. | 0 min, % . | . | 10 min, % . | . | 30 min, % . | . | 60 min, % . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecule . | L-CD31+ . | L-mock . | L-CD31+ . | L-mock . | L-CD31+ . | L-mock . | L-CD31+ . | L-mock . | ||||
| CD38 | 5.3 ± 3.2 | 7.4 ± 3.8 | 58.2 ± 9.1 | 8.3 ± 4.8 | 65.5 ± 11.4 | 12.7 ± 7.5 | 22.2 ± 9.7 | 9.1 ± 5.9 | ||||
| CD19 | 8.6 ± 4.1 | 5.9 ± 2.4 | 44.3 ± 8.7 | 9.5 ± 6.3 | 57.9 ± 8.9 | 7.5 ± 5.4 | 15.6 ± 8.4 | 5.7 ± 4.4 | ||||
| slgM | 6.5 ± 4.3 | 6.8 ± 2.7 | 37.9 ± 11.4 | 7.8 ± 1.4 | 44.6 ± 7.9 | 3.2 ± 2.8 | 18.8 ± 6.9 | 7.4 ± 3.9 | ||||
| HLA class I | 4.7 ± 2.8 | 7.1 ± 3.3 | 7.5 ± 5.9 | 8.4 ± 4.2 | 4.2 ± 3.5 | 8.4 ± 5.2 | 9.3 ± 3.5 | 6.6 ± 5.1 | ||||
Quantification (percentage) of cell conjugates in which the indicated molecule was relocalized at the B-CLL/L-fibroblast contact areas. At least 100 conjugates from 5 independent experiments (patient nos. 2, 4, 6, 7, and 9) were analyzed. Results correspond to the arithmetic mean ± SD.